PDE6G

PDE6G provides instructions for making the gamma subunit of an enzyme called rod cyclic GMP-phosphodiesterase, often shortened to PDE6. This enzyme is built from catalytic alpha and beta subunits together with two identical gamma subunits that hold its activity in check. The enzyme works inside rod photoreceptors, the retinal cells responsible for vision in dim light and at night. It is a key step in phototransduction, the chain of chemical events that converts captured light into a nerve signal. The gamma subunit plays a positive role in keeping the enzyme working correctly, so losing it disrupts normal signaling in the rods. An older name for this gene, RP57, reflects its recognized connection to retinitis pigmentosa. PDE6G is also active in some tissues outside the retina, but its role in vision is what matters for inherited retinal disease.

RP linked to PDE6G follows an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) pattern, meaning a person typically has a harmful change in both copies of the gene before disease appears. In the family where PDE6G was first tied to human disease, affected people had markedly narrowed visual fields and greatly reduced or absent electroretinogram (definition: A test (often abbreviated ERG) that measures the retina's electrical response to light, used to check how well photoreceptors are working.) responses, a test that measures how the retina reacts to light. Their eye examinations showed the classic features of RP, including bone spicule-shaped pigment deposits in the retina and pallor of the optic disc. Some also had swelling in the central retina, called cystoid macular edema, which can affect detailed central vision. A separate report described an 8-year-old boy with poor vision, strong farsightedness with astigmatism, and the same bone spicule pigment changes, caused by two different PDE6G changes inherited one from each parent. The severe forms of PDE6-related RP have been described as beginning as early as about 4 years of age, though the exact timing and course vary from person to person.

The link between PDE6G and retinitis pigmentosa is established. The connection was first shown in 2010 in an extended consanguineous family, where a splice-site change in PDE6G was found in all affected relatives and was shown in the laboratory to disrupt how the gene is read. This finding confirmed that the gamma subunit is needed to maintain normal PDE6 enzyme activity in people, not just in laboratory studies. PDE6G belongs to a well-studied group of phototransduction genes in which harmful changes are a recognized cause of inherited retinal disease. Overall, the PDE6 genes as a group account for a measurable minority of autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) RP, while PDE6G specifically remains a rare cause.

Because PDE6G-related RP has been reported in only a small number of families, the full range of severity, age of onset, and speed of progression is not yet well defined. How a particular genetic change translates into a particular course of vision loss cannot be predicted precisely from the current evidence. Much of the detailed biology of PDE6G loss comes from laboratory and animal studies, which help explain the mechanism but cannot substitute for long-term observation in people.

As of the date of this review, no therapy targeting PDE6G has been approved, and the reviewed records do not identify a gene-specific treatment. Researchers have developed a mouse model lacking Pde6g, in which rods degenerate early and rapidly and the disease closely mirrors the progression seen in people with RP. Such models are important research tools for understanding how the disease unfolds and for testing possible treatments, but they are not themselves treatments available to patients.

• First proof that PDE6G changes cause RP in people

  Human genetic study of one extended family with laboratory confirmation.

  What was found:

  They found a splice-site change in PDE6G that was present in all affected relatives, and laboratory testing confirmed it disrupts how the gene is read; affected people had constricted visual fields, severely reduced or absent retinal responses, bone spicule pigment, and macular swelling.

  Why it matters:

  This established PDE6G as a confirmed cause of RP in humans and showed the gamma subunit is needed for normal retinal enzyme activity.

  Limitation: Findings come from a single family, so they cannot capture the full range of how the disease behaves across different people.

• A mouse model of PDE6G-related retinal degeneration

  Preclinical animal study.

  What was found:

  The mice showed early and rapid loss of rod photoreceptors, followed by remodeling of the retina, changes in supporting cells, and blood vessel changes, closely mirroring the progression of human RP.

  Why it matters:

  It provides a research tool to study the disease mechanism and, potentially, to test future treatments.

  Limitation: Findings in mice do not always translate directly to people and do not represent an available therapy.

• A second human case broadens the genetic picture

  Single case report.

  What was found:

  He carried two different PDE6G changes, a frameshift change from his mother and a segment deletion from his father, together causing autosomal recessive RP with typical bone spicule pigment.

  Why it matters:

  It confirms PDE6G disease can result from combining two different harmful changes and expands the known ways the gene can cause RP.

  Limitation: A single patient cannot define typical onset or progression, and long-term outcome was not reported.

• Review of vision genes involved in phototransduction

  Narrative review.

  What was found:

  It placed PDE6G among the recognized phototransduction genes whose harmful changes lead to inherited retinal disease, each with distinct mechanisms and clinical features.

  Why it matters:

  It offers context for where PDE6G fits among related genes and confirms its established role.

  Limitation: A review summarizes existing work rather than providing new patient data specific to PDE6G.

• How often PDE6 genes cause recessive RP

  Review chapter.

  What was found:

  It noted that most recessive RP genes are individually rare, while the PDE6 group (PDE6A, PDE6B, PDE6G) is among those with somewhat higher prevalence, and described classic RP findings such as narrowed vessels and pigment deposits.

  Why it matters:

  It helps patients understand that PDE6G is one of several PDE6 genes and remains a relatively uncommon cause of RP.

  Limitation: Prevalence figures are broad and grouped, not specific to PDE6G alone.

Because PDE6G-related RP is inherited in an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) way, both parents of an affected child are usually unaffected carriers, and siblings may wish to discuss carrier testing with a genetic counselor. Since this form of RP can begin in childhood, families of a young child may find it helpful to plan early for vision support in learning and daily activities. Beyond these points, the general guidance shown on every gene page applies.

• Does my genetic result confirm that both copies of PDE6G are affected, and are the specific changes considered disease-causing?
• Given my current vision and test results, what course of RP might be reasonable to expect and monitor for?
• Should I be checked for cystoid macular edema, and is it something that can be treated if it appears?
• What schedule of eye examinations and functional testing do you recommend to track any change over time?
• Would genetic counseling for my family members be helpful, given the autosomal recessive inheritance?
• Are there any registries or studies relevant to PDE6G or phototransduction-related RP that I could learn more about?

If a PDE6G result is part of your care, confirming it and understanding its meaning with a genetic counselor or retinal specialist is a reasonable next step. Genetic testing and counseling can clarify the specific changes involved and what they may mean for you and your relatives. Because RP progresses over time, regular follow-up with an eye specialist helps track changes and address issues such as macular swelling if they arise. To explore studies that may be relevant, you can use RP Hope's Clinical Trials Finder with PDE6G preselected.